S-100 Protein: Serum Marker of Focal Brain Damage After Ischemic Territorial MCA Infarction

Büttner, Thomas; Weyers, Stephan; Postert, Thomas; Sprengelmeyer, Reiner; Kühn, Wilfried

doi:10.1161/01.str.28.10.1961

Cited by 237 publications

(187 citation statements)

References 31 publications

Supporting

Mentioning

164

Contrasting

Unclassified

Order By: Relevance

“…It is well known that S100B values increase in ischemic stroke, reaching maximum levels 2 to 4 days after onset, correlating with infarct size 4,6,13) . S100 protein level fell significantly thereafter, but still above the level seen in the control population at 3 months after stroke, suggesting partial restoration of glial cell integrity 3) .…”

Section: Discussionmentioning

confidence: 98%

Prognostic Value of Serum S100 Protein by Elecsys S100 Immunoassay in Patients with Spontaneous Subarachnoid and Intracerebral Hemorrhages

Yoon

Choi

Shim

et al. 2008

J Korean Neurosurg Soc

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

Prognostic Value of Serum S100 Protein by Elecsys S100 Immunoassay in Patients with Spontaneous Subarachnoid and Intracerebral Hemorrhages

Yoon

Choi

Shim

et al. 2008

J Korean Neurosurg Soc

View full text Add to dashboard Cite

“…Previous studies have reported increased plasma or serum neurobiochemical markers, e.g., S-100 protein, neuron-specific enolase, and N-acetylaspartate, in the peripheral circulation of patients after stroke but failed to demonstrate that these markers offered any additional advantage over current clinical assessment scales, risk factors, or neuroradiologic techniques (5)(6)(7)(8). Correlations have been observed between marker values, infarct size, and NIHSS scores, and increased concentrations predict disability and mortality.…”

Section: Discussionmentioning

confidence: 99%

“…The blood-brain barrier is compromised in many patients with stroke, and the liberation of neurobiochemical protein markers into the circulation may allow the pathophysiology, progress, and prognosis of patients with cerebrovascular disease to be further evaluated (5)(6)(7)(8). Although increased concentrations of several neurobiochemical protein markers have been detected in the peripheral blood of patients with stroke, to date none has found a place in clinical practice.…”

mentioning

confidence: 99%

Prognostic Use of Circulating Plasma Nucleic Acid Concentrations in Patients with Acute Stroke

et al. 2003

View full text Add to dashboard Cite

Background: At present there is no simple, accurate blood test that may be used to determine the severity of stroke or to predict mortality and morbidity in stroke patients presenting to emergency departments. Methods: Patients with stroke-like symptoms who presented to an emergency department of a university hospital in Hong Kong were recruited for the study. DNA extracted from patients' plasma was analyzed for the ␤-globin gene with a fluorescent-based PCR test. The primary outcome measures were in-hospital and 6-month mortality and morbidity using the post-stroke modified Rankin Score. Results: Among the 88 consecutive patients recruited to the study, 70 (80%) had ischemic stroke, 11 (13%) had intracerebral hemorrhage, and 7 (8%) had transient ischemic attacks. Median plasma DNA concentrations taken within 3 h of symptom onset were higher in patients who died compared with those who survived at discharge (6205 vs 1334 kilogenome-equivalents/L; P ‫؍‬ 0.03). Among patients with NIH Stroke Scale scores >8, median plasma DNA concentrations were higher in patients who died compared with those who survived to 6 months (2273 vs 968 kilogenome-equivalents/L; P ‫؍‬ 0.002). Plasma DNA concentrations correlated with the volume of cerebral hematoma (r ‫؍‬ 0.66; P ‫؍‬ 0.03). Plasma DNA concentrations >1400 kilogenome-equivalents/L had a sensitivity of 100% and a specificity of 74.4% for predicting hospital mortality after stroke, and the area under the ROC curve was 0.89 (95% confidence interval, 0.80 -0.94). The adjusted odds ratio for plasma DNA concentrations predicting 6-month mortality was

show abstract

“…Several studies have demonstrated that serum S100B concentrations are increased significantly following stroke (75)(76)(77)(78)(79)(80)(81)(82), with secretion of S100B increasing up to 48 h after symptom onset and the peak concentration occurring within the first 24 h after cerebral infarction. Elting et al (78 ) reported that patients who had a TIA or normal brain CT at presentation had significantly lower S100B concentrations with minimal variation over time, in comparison with individuals who had major neurological deficits and abnormal brain imaging showing large-artery cortical infarcts.…”

Section: Matrix Metalloproteinmentioning

confidence: 99%

Stroke Biomarkers: Progress and Challenges for Diagnosis, Prognosis, Differentiation, and Treatment

2010

View full text Add to dashboard Cite

Background: Stroke is a devastating condition encompassing a wide range of pathophysiological entities that include thrombosis, hemorrhage, and embolism. Current diagnosis of stroke relies on physician clinical examination and is further supplemented with various neuroimaging techniques. A single set or multiple sets of blood biomarkers that could be used in an acute setting to diagnosis stroke, differentiate between stroke types, or even predict an initial/reoccurring stroke would be extremely valuable. Content: We discuss the current classification, diagnosis, and treatment of stroke, focusing on use of novel biomarkers (either solitary markers or multiple markers within a panel) that have been studied in a variety of clinical settings. Summary: The current diagnosis of stroke remains hampered and delayed due to lack of a suitable mechanism for rapid (ideally point-of-care), accurate, and analytically sensitive biomarker-based testing. There is a clear need for further development and translational research in this area. Potential biomarkers identified need to be transitioned quickly into clinical validation testing for further evaluation in an acute stroke setting; to do so would impact and improve patient outcomes and quality of life.

show abstract

S-100 Protein: Serum Marker of Focal Brain Damage After Ischemic Territorial MCA Infarction

Cited by 237 publications

References 31 publications

Prognostic Value of Serum S100 Protein by Elecsys S100 Immunoassay in Patients with Spontaneous Subarachnoid and Intracerebral Hemorrhages

Prognostic Value of Serum S100 Protein by Elecsys S100 Immunoassay in Patients with Spontaneous Subarachnoid and Intracerebral Hemorrhages

Prognostic Use of Circulating Plasma Nucleic Acid Concentrations in Patients with Acute Stroke

Stroke Biomarkers: Progress and Challenges for Diagnosis, Prognosis, Differentiation, and Treatment

Contact Info

Product

Resources

About